The independent source for health policy research, polling, and news.
81-100 of 1,311 results
A new drug is helping families who’ve spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress — and a broader understanding of obesity — is now under threat as the government dismantles the pipeline for promising new research.
The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health budgets, and withdraws funding for bird flu vaccines, health security experts said.
Worried that President Donald Trump’s FDA might not act, a panel of cancer experts recommended that doctors consider testing before dosing patients with a commonly used but sometimes deadly cancer drug. It came too late for many patients.
Late last year, South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state programs covering these effective but expensive drugs. But access remains limited, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.
One thing experts agree on: The damage from the funding cuts will be varied and immense.
According to the timeline in the May 12 executive order, prescription drug price reductions would not happen "almost immediately,” but rather could take months or years. And extending the savings to Americans outside federal health insurance programs such as Medicare would likely require congressional action.
While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account for 90% of U.S. prescriptions — see trouble ahead for patients.
GOP-controlled House committees approved parts of President Donald Trump’s “one big, beautiful bill” this week, including more than $700 billion in cuts to health programs over the next decade — mostly from Medicaid, which covers people with low incomes or disabilities. Meanwhile, Health and Human Services Secretary Robert F. Kennedy Jr. testified before Congress for the first time since taking office and told lawmakers that Americans shouldn’t take medical advice from him. Julie Appleby of KFF Health News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine join KFF Health News’ Julie Rovner to discuss these stories and more.
Michael Kestner, CEO of Pain MD, was convicted of 13 fraud felonies after his company gave patients hundreds of thousands of questionable injections at clinics in Tennessee, Virginia, and North Carolina.
A new training program teaches workers to stop the baby talk and address older people as adults.
Republicans on Capitol Hill are struggling to reach consensus on cutting the Medicaid program as they search for nearly a trillion dollars in savings over the next decade — as many observers predicted. Meanwhile, turmoil continues at the Department of Health and Human Services, with more controversial cuts and personnel moves, including the sudden nomination of Casey Means, an ally of Robert F. Kennedy Jr.’s, to become surgeon general. Anna Edney of Bloomberg News, Maya Goldman of Axios, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Lauren Sausser, who co-reported the latest “Bill of the Month” feature, about an unexpected bill for what seemed like preventive care.
When a New York physician was indicted for shipping abortion medications to a woman in Louisiana, it stoked fear across the network of doctors and medical clinics who engage in similar work. But some physicians vowed not to stop.
Secretary Robert F. Kennedy Jr.’s HHS said an enormous, noncompetitive flu vaccine development grant to two favored NIH leaders would ensure “transparency, effectiveness, and comprehensive preparedness.” But their vaccine is in early stages, relies on old technology, and is just one of scores of similar efforts.
The Department of Health and Human Services underwent an unprecedented purge this week, as thousands of employees from the National Institutes of Health, the FDA, the Centers for Disease Control and Prevention, and other agencies were fired, placed on administrative leave, or offered transfers to far-flung Indian Health Service facilities. Altogether, the layoffs mean the federal government, in a single day, shed hundreds if not thousands of combined years of health and science expertise. Lauren Weber of The Washington Post, Rachel Cohrs Zhang of Bloomberg News, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ Julie Rovner to discuss this enormous breaking story and more. Also this week, Rovner interviews KFF Health News’ Julie Appleby, who reported and wrote the latest “Bill of the Month” feature about a short-term health plan and a very expensive colonoscopy.
The rate of overdose deaths from opioids has grown significantly among Black people. Yet, even after a nonfatal overdose, this group is half as likely to be referred to or get treatment compared with white people. Advocates and researchers cite implicit bias, insurance denials, and other systemic issues.
A bill designed to force PBMs to pay higher fees to independent drugstores sailed through the state House, but lobbyists are marshaling their forces to kill the measure in the Senate.
It’s the Trump administration vs. the federal courts, as the Department of Government Efficiency continues to try to cancel federal contracts and programs and fire workers. But in the haste to cut things, jobs and programs are being eliminated even if they align with the new administration’s goal to “Make America Healthy Again.” Jessie Hellmann of CQ Roll Call, Sarah Karlin-Smith of the Pink Sheet, and Rachel Roubein of The Washington Post join KFF Health News’ Julie Rovner to discuss these stories and more.
Two senior scientists say National Institutes of Health officials advised them to remove references to mRNA vaccines in grant applications, and they fear the Trump administration will abandon a promising field of medical research.
The FDA is already limited in policing claims of health benefits by makers of supplements and herbal remedies — a $70 billion industry. Get ready for even less regulation.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
© 2026 KFF